Obesity, cardiovascular risk and pharmacotherapy

Blood Pressure

Volumn 11, Issue 5, 2002, Pages 260-262

  Ruilope, Luis M ^a   Garcia Robles, Rafael ^a   Moreno, Basilio ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; LIPID; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BLOOD PRESSURE REGULATION; BODY MASS; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION ANALYSIS; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG USE; DYSLIPIDEMIA; EDITORIAL; FEMALE; HEALTH CARE COST; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DISEASE; LIFESTYLE; MALE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COUNSELING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SODIUM RESTRICTION; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; CARDIOVASCULAR DISEASES; CYCLOBUTANES; HUMANS; LACTONES; OBESITY; RISK FACTORS;

EID: 0036431093     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370502320779458     Document Type: Editorial

References (41)

1. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286: 1195-200.
2. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in aprospective cohort of US adults. N Eng J Med 1999; 341: 1097-105.
3. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001; 161: 1581-6.
4. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 713-18.
5. Luque M, Garcia-Robles R, Tamargo J, Ruilope LM. Blood pressure control in hospital located hypertension units. Hypertension 2001; 37: 1030 (abstract).
6. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46.
7. Guidelines Subcommittee, World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83.
8. Kambham N, Markowitz, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-509.
9. Quesenberry CP Jr, Caan B, Jacobson A. Obesity, health service use, and health care costs among members of a health maintenance organization. Arch Intern Med 1998; 158: 466-72.
10. Tuomilehto J, Lindström J, Eriksson JG, et al., for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucoase tolerance. N Eng J Med 2001; 344: 1343-50.
11. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Eng J Med 2001; 345: 790-7.
12. Van Gaal LF, Wauters M, DeLeeuw I. The benefitial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997; 21 Suppl 1: S5-9.
13. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high- normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 1997; 157: 657-67.
14. Reisin E, Abel R, Modan M, Silverberg DS, Eliahou HE, Modan B. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Eng J Med 1978; 298: 1-6.
15. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358: 1682-6.
16. Jeffery RW. Weight management and hypertension. Ann Behav Med 1991; 13: 18-22.
17. Pickering TG. Obesity and hypertension: What should we do? Ann Intern Med 2001; 134: 72-4.
18. Johannesson M, Agewall S, Hartford M, Hedner T, Fagerberg B. The cost-effectiveness of a cardiovascular multiple-risk-factor intervention programme in treated hypertensive men. J Intern Med 1995; 237: 19-26.
19. Schmieder RE, Gatzka C, Schachinger H, Schobel H, Ruddel H. Obesity as a determinant for response to antihypertensive treatment. Br Med J 1993; 307: 537-40.
20. Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens 2001; 19: 667-74.
21. O'Keefe JH, Wetzel M, Moe RR, Brosnahan K, Lavie CJ. Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? J Am Coll Cardiol 2001; 37: 1-8.
22. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Eng J Med 2000; 342: 145-53.
23. Reisin E, Weir MT, Falkner B, Hutchinson HG, Anzalone DA, Tuck ML. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients with Hypertension (TROPHY) Study Group. Hypertension 1997; 30: 140-5.
24. Koop CE. Guidance for treatment of adult obesity. Shape up America! Bethesda, MD: Wyeth-Ayerst Laboratories, 1996.
25. Glazer G. Long-term pharmacotherapy of obesity 2000. Arch Intern Med 2001; 161: 1814-24.
26. Lean ME. Sibutramine - a review of clinical efficacy. Int J Obes Relat Metab Disord 1997; 21 Suppl: S30-6.
27. Hauptman JB, Jeunet FS; Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992; 55 Suppl: 309-13S.
28. McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo controlled, multicenter trial. Arch Intern Med 2000; 160: 2185-91.
29. Hazenberg BP. Randomized, double blind, placebo controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 2000; 94: 152-8.
30. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, and the Sibutramine in Hypertensives Clinical Study Group. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002; 16: 5-11.
31. Sramek JJ, Leibovitz MT, Weinstein SP, et al. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. J Hum Hypertens 2002; 16: 13-19.
32. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens 1998; 16: 2013-17.
33. Lindgärde F, On Behalf of the Orlistat Swedish Multimorbidity Study Group. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000; 248: 245-54.
34. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000; 8: 49-61.
35. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-42.
36. McLaughlin T, Abbasi F, Kim HS, Lamendola C, Schaaf P, Reaven G. Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy obese women. Metabolism 2001; 50: 795-800.
37. Blackburn G. Effect of degree of weight loss on health benefits. Obes Res 1995; 3 Suppl 2: 211-16S.
38. Goldstein DJ. Beneficial health effects of moderate weight loss. Int J Obes Relat Metab Disor 1992; 16: 397-415.
39. Foster GD, Wadden TA, Vogt RA, Brewer G. What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 1997; 65: 79-85.
40. Bray GA. Sibutramine and blood pressure: a therapeutic dilemma. J Hum Hypertens 2002; 16: 1-3.
41. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol 1995; 141: 1128-41.